| Size | Price | Stock | Qty |
|---|---|---|---|
| 25g |
|
||
| Other Sizes |
| Targets |
Microbial Metabolite Human Endogenous Metabolite
The primary target of tryptophol is the human endogenous metabolite system. As an aromatic alcohol, it may interact with neurotransmitter systems, particularly those involving serotonin and other indole derivatives. It has been reported to have hypnotic effects, suggesting potential interactions with the central nervous system. |
|---|---|
| ln Vitro |
In vitro, tryptophol is used as a reactant for the preparation of inhibitors of the C-terminal domain of RNA polymerase II, which have antitumor activities. It is also used in the synthesis of anti-HIV-1 agents. The compound's indole structure makes it a valuable building block in medicinal chemistry and natural product research.
|
| ln Vivo |
In vivo, tryptophol has been reported to have hypnotic effects in humans, acting as a sleep-inducing compound. It is formed endogenously and may contribute to the regulation of sleep-wake cycles. As a metabolite of Candida albicans, it may also play a role in the pathogenesis of fungal infections.
|
| Enzyme Assay |
In vitro enzyme assays for tryptophol typically involve studying enzymes that metabolize indole derivatives, such as cytochrome P450 enzymes or alcohol dehydrogenases. The compound is used as a substrate to measure enzyme activity, and the reaction products are analyzed by chromatographic or spectroscopic methods. It may also be used in assays to study the inhibition of RNA polymerase II.
|
| Cell Assay |
In vitro cell experiments with tryptophol involve treating cell lines with the compound to assess its cytotoxic, antitumor, or antiviral activities. Cells are cultured with varying concentrations of tryptophol, and cell viability, proliferation, and apoptosis are measured. The compound's effects on RNA polymerase II activity and viral replication may also be evaluated.
|
| Animal Protocol |
In vivo animal experiments with tryptophol are not extensively documented. The compound's hypnotic effects have been reported in humans, suggesting that animal models of sleep may be used to study its pharmacological properties. Animal models of fungal infection may also be used to study the role of tryptophol in Candida pathogenicity.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for tryptophol are limited. As a small, lipophilic molecule, it is expected to be readily absorbed and distributed in the body, including the central nervous system. It is soluble in methanol, ethanol, ether, acetone, chloroform, and ethyl acetate, and slightly soluble in water. The compound is sensitive to light.
|
| Toxicity/Toxicokinetics |
Toxicological data for tryptophol are limited. As an endogenous metabolite and a compound found in foods, it is generally considered to have low toxicity. However, comprehensive toxicological studies have not been performed. The compound is intended for research use only.
|
| Additional Infomation |
Tryptophol is an indole alcohol, a product of ethanol with 1H-indole-3-yl substitution at the 2-position. It is a metabolite of Saccharomyces cerevisiae, as well as a auxin and plant metabolite. Tryptophol has been reported to exist in Paraphaeosphaeria minitans, Balansia epichloe, and other organisms with relevant data. Tryptophol is a metabolite found or produced in Saccharomyces cerevisiae.
Tryptophol is a research compound with applications in medicinal chemistry, natural product research, and microbiology. It is used as a building block for the synthesis of antitumor and anti-HIV agents. No clinical trials or approved therapeutic indications exist for this compound. Its mechanism of action includes hypnotic effects and potential interactions with indole-related neurotransmitter systems. |
| Molecular Formula |
C10H11NO
|
|---|---|
| Molecular Weight |
161.20
|
| Exact Mass |
161.084
|
| CAS # |
526-55-6
|
| PubChem CID |
10685
|
| Appearance |
Solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
357.8±17.0 °C at 760 mmHg
|
| Melting Point |
59 °C
|
| Flash Point |
170.2±20.9 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.674
|
| LogP |
1.28
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
12
|
| Complexity |
149
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C2C(=C1)C(=CN2)CCO
|
| InChi Key |
MBBOMCVGYCRMEA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H11NO/c12-6-5-8-7-11-10-4-2-1-3-9(8)10/h1-4,7,11-12H,5-6H2
|
| Chemical Name |
2-(1H-indol-3-yl)ethanol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (620.35 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3.25 mg/mL (20.16 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 32.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 2: ≥ 2.5 mg/mL (15.51 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (15.51 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 66.67 mg/mL (413.59 mM) in 50% PEG300 50% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.2035 mL | 31.0174 mL | 62.0347 mL | |
| 5 mM | 1.2407 mL | 6.2035 mL | 12.4069 mL | |
| 10 mM | 0.6203 mL | 3.1017 mL | 6.2035 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
